Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

Y0001591

Flutamide for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Flutamide, 2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C11H11F3N2O3
CAS Number:
13311-84-7
Molecular Weight:
276.21
MDL number:
MFCD00072009
UNSPSC Code:
41116107
PubChem Substance ID:
329831499
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

flutamide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O

InChI

1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)

InChI key

MKXKFYHWDHIYRV-UHFFFAOYSA-N

Gene Information

human ... AR(367)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Flutamide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Signal Word

Warning

Hazard Statements

H302,H351,H361,H373,H411

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 2 - Carc. 2 - Repr. 2 - STOT RE 2

Target Organs

Liver

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R N Brogden et al.
Drugs, 38(2), 185-203 (1989-08-01)
Flutamide is a non-steroidal antiandrogenic drug devoid of hormonal agonist activity. Flutamide appears to be a specific antiandrogen only at androgen-dependent accessory genital organs. Its pharmacological activity is due substantially to the principal metabolite, 2-hydroxyflutamide. In comparative trials involving small
R Neri
Urology, 34(4 Suppl), 19-21 (1989-10-01)
Flutamide is rapidly metabolized by hydroxylation of the side chain to SCH 16423 (alpha, alpha, alpha-trifluoro-2-methyl-4'-nitro-m-lactotoluidide), the major metabolic product in all species studied, which is biologically active in vivo and in vitro studies. Flutamide exhibits its antiandrogenic activity by
Reiko Anahara et al.
Reproductive toxicology (Elmsford, N.Y.), 25(2), 139-143 (2008-02-05)
This is a mini-review summarizing recent findings on the effect of flutamide (FLUT), an anti-androgenic toxicant, on the mouse testis, particularly on the ectoplasmic specialization (ES) in the testis. FLUT induces a reduction in the weight of male reproductive tissues
K P Delaere et al.
Seminars in oncology, 18(5 Suppl 6), 13-18 (1991-10-01)
Little is known about the efficacy of flutamide monotherapy in previously untreated patients with prostatic carcinoma. In this study, 40 patients with advanced disease were treated with 250 mg flutamide, three times daily. The mean follow-up was 7 months. After
F Labrie et al.
Journal of steroid biochemistry, 33(4B), 817-821 (1989-10-01)
In order to achieve a more complete blockade of androgens of both testicular and adrenal origins, 223 patients with advanced prostate cancer (stage D2 with bone metastases) received the combination therapy with the antiandrogen Flutamide and the LH-RH agonist [D-Trp6,des-Gly-HN10(2)]
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service